The Modern DMTA Cycle: Why MedChem Works Better When Biology, CADD and DMPK Share the Same Clock
The Modern DMTA Cycle: Why MedChem Works Better When Biology, CADD and DMPK Share the Same Clock The design–make–test–analyze (DMTA) cycle is the core engine of small molecule drug discovery, but it delivers value only when all components move in sync and data is interpreted collectively. When design is delayed by late DMPK insights, biology […]
Read MoreProtein Quality Is Program Quality: Gene-to-Structure Strategies for Better Discovery Decisions
Protein Quality Is Program Quality: Gene-to-Structure Strategies for Better Discovery Decisions High-quality protein is one of the most important foundations in drug discovery. It affects assay performance, screening reliability, biophysical measurements, crystallography and structure-based design. Poor protein quality can create false negatives, false positives, irreproducible data and misleading SAR. Protein sciences therefore influence the entire […]
Read More